Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate the effectiveness, safety and tolerability of a combination drug product (SM-1) containing diphenhydramine, zolpidem and lorazepam, in adult participants who sometimes have difficulty in falling asleep or staying asleep, but who do not have chronic insomnia. Participants will receive SM-1 or a combination of diphenhydramine and lorazepam during 2 one-night stays at a sleep center.


Clinical Trial Description

The purpose of this study is to evaluate the effect of a combination drug product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam on total sleep time, and to determine the contribution of zolpidem to the combination, using a 3-hour Phase Advance model of sleep challenge with 8 hours of polysomnographic (PSG) recording. This is a 2-arm, 2-period crossover trial including the 3-drug investigational product and a 2-drug comparator. The 2 arms are: investigational combination product, and a 2-drug comparator containing diphenhydramine and lorazepam but not zolpidem. Participants will be adults who sometimes have difficulty falling asleep or staying asleep, but who are generally healthy and do not have chronic insomnia or sleep apnea.

A total of 14 subjects are planned to enroll in the study. Subjects who qualify for participation will be asked to keep a sleep diary to document their sleep times leading up to their first overnight stay in the sleep center and during the study. Subjects will be asked to spend at least 7.5 hours in bed at a regular bedtime during the study. Qualifying participants also will not anticipate traveling across 3 time zones, be involved in night shift work, or significant disruptions in their sleep schedules during the study. The study requires 2 one-night stays in a sleep center in New York City, for administration of the study treatments and PSG & EEG measurements. Qualifying subjects will anticipate being able to return to the sleep center, located in Manhattan, for a total of 3 visits, including initial screening and 2 treatment times.

Subjects will receive a follow up phone call from study staff 3 days after final dose of study medication.

During each sleep center visit, subjects will arrive to the sleep center approximately 5 hours prior to their average usual bedtime and will be given their study treatment. Their sleep will be monitored for 8 hours. Each subject will receive both treatments, although the sequence of the 2 treatments will be randomized. Both subjects and study personnel monitoring the subjects will be blinded to the identity of the treatment administered at each visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04396327
Study type Interventional
Source Sequential Medicine Ltd
Contact Clinilabs Drug Development Corporation
Phone (212)994-4567
Email participate@clinilabs.com
Status Not yet recruiting
Phase Phase 2
Start date May 27, 2020
Completion date June 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT03331042 - SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia. Phase 3
Completed NCT00594022 - Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness N/A
Completed NCT00163046 - A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance Phase 3
Completed NCT00666770 - A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance Phase 3
Completed NCT00667108 - A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance Phase 3
Completed NCT00666939 - A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance Phase 3
Recruiting NCT05457790 - Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD) N/A
Withdrawn NCT03338764 - An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia Phase 3
Completed NCT01779830 - A Study of LY2624803 in Participants With Transient Insomnia Phase 1
Completed NCT00674752 - A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia Phase 3
Completed NCT00666575 - A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness Phase 3
Completed NCT00671398 - Efficacy of Ramelteon on Transient Insomnia in Healthy Adults Phase 3
Completed NCT00659100 - A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment Phase 3